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Introduction
Cystic fibrosis (CF) is an autosomal recessive disease that is the most common cause of death in Caucasian children and young adults. The disease is caused by mutations in a gene encoding a 170-kDa cAMP-regulated Cl − channel that has been designated as the cystic fibrosis transmembrane conductance regulator (CFTR). 1, 2 Studies of the epithelial cells from patients with CF have shown that mutations in the CFTR gene cause defective regulation of Cl − permeability across apical membranes. [3] [4] [5] Although CF affects all organs containing epithelial cells, lung disease is the major cause of morbidity. 6 Recent studies have suggested that deficiency of Cl − re-absorption in airway epithelia results in hypertonic secretion. This high-salt environment causes the inactivation of defensins, a group of salt-sensitive proteins that inhibit microbe pathogens in the lung airways. 7 Consequently, bacteria colonize the airways and induce neutrophil-dominated inflammatory responses, thick purulent mucus and progressive loss of airway function. 6, 8 long-term relief for patients by expressing the normal gene in the diseased cells to restore the CFTR function. The feasibility of gene transfer to lung epithelial cells was initially demonstrated by the findings that expression of the wild-type CFTR cDNA corrected the chloride channel defect in vitro using retrovirus or adenovirus vectors. [10] [11] [12] However, gene therapy of CF in patients has not been successful due to the limitations of the current vector systems.
A number of vector systems have been studied for gene therapy of CF, including liposomes, recombinant adenovirus and adeno-associated virus (AAV). While liposomes are capable of delivering genes into cultured cells efficiently, they are currently inefficient in transducing airway epithelial cells in vivo, and have been reported to cause toxicity at high doses. 13 Adenoviral vectors can infect airway epithelium efficiently. [14] [15] [16] [17] [18] However, these vectors have been shown to induce inflammatory responses in animal models and in patients. 19, 20 These side-effects have been attributed to the leaky expression of the residual viral genes carried by the vectors. 21 In contrast, an AAV vector has not only been shown to infect airway cells efficiently, but the vector DNA persisted for weeks in animal models. 22, 23 Recent phase I clinical trials also have shown delivery of the CFTR gene into epithelial cells. 24 The delivered CFTR cDNA persisted over 70 days based on PCR detection of vector DNA. The ongoing trial at Johns Hopkins University has also shown that AAV vector administrations into lungs are safe and well tolerated in all patients. 25 In addition to the natural airway tropism and non-pathogenic nature, other major advantages of AAV include: (1) infection of non-dividing cells; (2) persistent gene expression through integration into the cellular chromosomes or by conversion into double-stranded episomal forms; (3) delivery of the therapeutic gene without co-transfer of any viral genes. This makes AAV vector to be unlikely to induce inflammatory responses by the host against the transduced cells. Indeed, experiments with rAAV-mediated gene transfer into skeletal muscles have shown persistent transgene expression with no inflammatory responses in animal models. [26] [27] [28] In spite of these advantages, the efficacy of AAV/CFTR vector for gene therapy is limited by it suboptimal expression of the CFTR gene. For example, no RNA transcripts could be detected in any of the treated patients in the clinical trials. This is mainly due to the limited packaging capacity of AAV, which did not allow packaging of the CFTR cDNA with a promoter sequence. Insertion of a promoter, such as the P5 promoter of AAV, resulted in a vector that is overall less efficient than a vector in which the CFTR gene is driven by only the inverted terminal repeat sequence (ITR) of AAV. 22, 29 This study was the basis for the choice of vector in current clinical trials. 24, 30 However, this atypical ITR promoter has a low transcriptional activity compared with promoters with standard consensus sequences. Therefore, this approach is a compromise, sacrificing the level of CFTR expression for the packaging efficiency of the AAV vector.
AAV can package a vector up to 5.0 kb, although the packaging efficiency decreases with increasing vector size. The essential sequences for an AAV vector are the two ITRs, each 145 bp in size. Therefore, a minimal-sized AAV vector can accommodate a transcriptional cassette, including promoter and polyadenylation signal, of 4.7 kb in size. As the cDNA of CFTR gene is 4.6 kb, and a poly-A signal is also essential, it has been difficult to incorporate an additional promoter with the CFTR cDNA into the AAV vector. In this report, we describe the development of second-generation AAV/CFTR vectors that contain short and efficient transcription elements to express a wild-type CFTR mini-gene. Transduction with these vectors produces high levels of CFTR expression and correction of the Cl − transport defects in CF airway epithelial cells. These new vectors should increase the efficacy for gene therapy of cystic fibrosis.
Results
Comparison of transcriptional activities of small promoters with the ITR sequence The total size of an AAV-cftr vector should be within the packaging size limit of AAV, that is under 5.0 kb. 31 As the size of the CFTR cDNA is 4.6 kb, it his been difficult to package the CFTR cDNA with an efficient promoter. In addition, current AAV vectors contain some nonessential sequences because of the difficulties in construction of an AAV vector with only the ITR sequences. As the non-essential sequences occupy some of the packaging capacity of AAV, it has not been possible to combine the CFTR gene with a promoter. Recently, we have constructed an ITR-only AAV vector that allowed us to package an insert of 4.7 kb (manuscript in preparation). This made it possible to incorporate transcriptional elements (promoter and poly-A) in the size of 250 bp into an AAV vector, since the coding sequence of CFTR is 4.45 kb. Our first goal was to identify efficient transcriptional elements with a total size of under 250 bp.
To obtain short promoters, we have conducted truncation analysis of viral promoters including CMVie, SV40e, HSVtk and AAV-P5 promoter. The size of each promoter is progressively reduced from the 5Ј-end, until loss of activity is observed. To include any potential influence of the ITR sequences on the promoter activity, the promoters were tested in the sequence background of an AAV vector. The levels of gene expression were analyzed with CAT assays in transfected HeLa cells. We have identified four short promoters that have significantly higher activity than the AAV ITR alone and are 102 bp to 200 bp in size. These promoters are the AAV-P5 (150 bp), SV40e (200 bp), TK1 (110 bp) and a second TK promoter (TK2) with an additional 10 bp deletion between the distal and the proximal element (102 bp). These short promoters were compared with AAV-ITR and a strong promoter, CMVie, for their levels of transcriptional activity (Figure 1 ). The CAT activity expressed from the ITR (Figure 1 lane ITR) was only a few fold over the background level defined by a CAT plasmid without any promoter (CAT-basic). The levels of CAT expression from TK1, P5 and SV40e are over 10-fold higher then the transcriptional activity of ITR alone.
Identifying an efficient short polyadenylation signal In order to obtain a short and efficient polyadenylation site, we have performed a truncation analysis of the poly-A sequence of herpes simplex virus tk gene. The sequences flanking the conserved AATAAA sequence and the polypurine tracts (see Refs 32 and 33 for a review) were truncated progressively until the levels of gene expression decreased. We have also tested two synthetic poly-A signals which contain duplicates of the conserved AATAA sequence and the polypurine tract but with shorter intertwining sequence than the TK poly-A. However, none of these synthetic poly-A signals provided high levels of mRNA stability (data not shown). In these experiments, poly-A signal activity was measured indirectly by assaying levels of CAT gene expression. We have identified an efficient polyadenylation signal of 65 bp in size, TK65 poly-A. Comparison of this short poly-A with a full-length SV40e or a BGH (bovine growth hormone) poly-A site is shown in Figure 2 . Truncated TK poly-A stabilized mRNA at the levels similar to those of the strong BGH or SV40e ploy A signal. Therefore, the combination of the TK1 or P5 promoter with TK65 poly-A signal provided us with an efficient transcriptional unit that is over 10 times more active than the ITR and is smaller than 250 bp in total size.
CFTR expression from an AAV vector
To express the CFTR protein from an AAV vector, we inserted the CFTR gene in combination with the TK65 poly-A and either TK1 or P5 promoter into the AAV vector, pAV53. As the coding sequence of the CFTR gene (from start codon to stop codon) is 4443 bp, 1 we were able to reduce further the size of CFTR cDNA from 4.7 kb to 4.467 kb by removing most of the untranslated regions from the cDNA. Only 20 bp of the untranslated region at the 5Ј-end was kept as they were essential for translation of the mRNA (see Materials and methods for details). This allowed us to insert CFTR gene with TK or P5 promoter while keeping the sizes of the vectors (4842 bp with TK, 4983 bp with P5) under the 5.0 kb packaging limit of AAV. The results from both SPQ and single-channel patch clamp demonstrated that the CFTR cDNA inserted into the AAV vector with either TK or P5 promoter was efficiently transferred and expressed in target cells.
CFTR is more efficiently expressed from short promoters than the ITR The transcriptional activities of the short promoters are higher than the promoter-like activity of the ITR sequence. This should translate into high levels of CFTR expression from the AAV vector. However, an AAV/cftr vector containing an additional promoter may be packaged less efficiently as it will be larger than AAV-cftr, the vector expressing the CFTR from ITR. To compare the efficiencies of CFTR transduction by the AAV vectors containing the P5 (AAVp5-cftr) with the AAV-cftr vector, we analyzed the levels of CFTR activity in vector-transduced cells using whole-cell patch clamp measurements. This technique provided us with a quantitative assay for comparing the numbers of CFTR channels in cells by measuring the amount of the Cl − current conducted. In these experiments, we produced AAVp5-cftr, AAVsv.cftr and AAV-cftr vectors under comparable conditions. The same amount of each vector suspension was used to infect equal numbers of cells in a 12-well dish. Three to five cells were patch-clamped from each population. The results are shown in Figure 5 . Patch clamp measurements of cells transduced with AAV-cftr or AAVp5-lacZ expressed no currents after forskolin stimulation (Figure 5a and b) . The current/voltage (I/V) step protocols showed no appreciable CFTR activity. In contrast, forskolin-induced Cl − currents were found in cells transduced with AAVp5-cftr (Figure 5c ). The recording of I/V step protocols and I/V relation (Figure 5d ) showed timeindependent current, which are typical characteristics of CFTR. Currents showed rectification due to the Cl gradient used (17:150 mm) according to the prediction of the constant field equation. On average, the forskolin-stimulated Cl − conductance in each transduced cell was 1.4 ± 0.12 nS (n = 3), which is equivalent to approximately 300 CFTR molecules per cells, assuming the open probability was 50% and the conductance of a single channel is 8 pS. IV relations of currents measured from the AAVp5-cftr infected cells also showed that the forskolinstimulated Cl − permeability was in the same range of normal airway surface epithelial cells (Figure 5d ). Cells transduced with AAVp5-cftr showed higher levels of CFTR activity than cells transduced with AAVsv.cftr (data not shown).
To determine the minimal titer required to produce a normal level of CFTR expression, we analyzed Cl − conductance in cells transduced with AAV vectors at MOIs of 1, 2 and 4. The levels of Cl − conductance in transduced cells increased with increasing vector titers (Figure 5e ). The levels of CFTR expression similar to that of normal airway epithelial cells were achieved at MOI of 4. In the controls, no appreciable CFTR expression was observed in cells transduced with either AAV-cftr or AAVp5-lacZ at MOI of 4. These results further showed that CFTR gene was efficiently expressed from AAVp5-cftr and CFTR defect in cells may be compensated in vitro with low titers of transducing virions.
The CFTR gene with a promoter is efficiently packaging into virions To compare directly the packaging efficiencies of the AAV/cftr vectors containing different promoters, we conducted packaging assay of the AAVp5-cftr, AAVsvcftr and AAV-cftr vectors. We also include AAVcmv-cftr in which the gene is driven by a large CMVie promoter (650 bp), as a control. The packaging efficiencies of these vectors were determined using a Southern blot analysis. We first produced comparable numbers of recombinant virions by packaging the vectors under identical conditions and infected the same number of cells with equal amount of viral suspension. This allowed the virions to uncoat naturally in cells. We then extracted the vector DNA from the infected cells with Hirt's extraction. The amounts of vector DNA in the infected cells directly represented the numbers of virions that contained functional vector DNAs. The results of this experiment are shown in Figure 6 . AAV-cftr, the vector that did not contain a promoter was efficiently packaged and transferred into target cells (lane 3). This clearly demonstrates that the low level of CFTR expression from AAV-cftr is not due to packaging deficiency but to the lack of sufficient transcription from the ITR. Although CMVie promoter would express the CFTR gene at high levels, it could not be packaged with the CFTR gene into an AAV vector (lane 4). In contrast, AAVp5-cftr and AAVsv-cftr were packaged into virions and transferred into the target cells, as indicated by the bands detected by the probe (lanes 5 and 6). AAVp5-cftr was more efficiently packaged than AAVsv-cftr as it is 50 bp smaller than the latter.
Correcting CFTR defects in CF epithelial cells
To demonstrate directly the correction of CFTR defects in CF airway epithelial cells, we have transduced JME cells with AAVp5-cftr and analyzed the CFTR function with whole patch clamp measurements. JME cells were isolated from the nasal polyp of a CF patient with a homozyote ⌬508 genotype. 34 These cells retain the characteristics of the nasal epithelial cells and do not express any functional CFTR. 11, [34] [35] [36] The typical results of whole cell patch analyses of AAVp5-cftr transduced JME cells are shown in Figure 7 . A normal level of forskolinstimulated Cl currents (120 pA) were detected in cells transduced with AAVp5-cftr at MOI approximately 8. The currents were blocked by the Cl channel blocker diphenylcarboxylate (DPC, 2 mm). The conductance was 60.6 ± 4.2 pS/pF, (n = 4). For comparison, we measured forskolin-activated CFTR-mediated conductance in non-CF airway epithelial cells (16HBE14o− cell line). These cells express normal CFTR and have characteristics of airway surface epithelial cells. 37 The forskolin-stimulated current was 130 pA and the conductance was 63.3 ± 4.2 pS/pF, (n = 3). In contrast, no forskolin-stimulated Cl currents were detected in JME cells that had not been transduced (Figure 7 , bottom trace). These results further confirmed that CFTR expression from AAVp5-cftr vector can efficiently correct the ⌬508 phenotype in airway epithelial cells, and the mutant proteins do not interfere with the functions of the normal CFTR.
Figure 5 Whole cell patch clamp recordings from HeLa cells infected with AAV vectors. (a) Recording from a cell infected with AAV-cftr. Whole cell current (left panel) was not affected by stimulation of cell with forskolin, which was present at the time indicated by the hatched bar. At breaks in current traces, current voltage (IV) step protocols were recorded. Under control and forskolin-stimulated conditions the measured currents yielded respective conductance of 234 pS (control, middle panel) and 228 pS (forskolin, right panel). (b) Recording from a cell that has been infected with AAVp5-lacZ. Forskolin stimulation of the cells did not activate whole cell current (left panel) and IV step protocols yielded conductance of 257 pS (control, middle panel) and 295 pS (forskolin, right panel). (c) Recording from a cell infected with AAV p5CFTR. Stimulation of the cell resulted in a reversible stimulation of outward current, which under the used conditions is carried by chloride influx. Stimulated current yielded a whole cell conductance of 1.53 nS. IV step protocols (right panels) showed time-independent currents that showed rectification owing to the employed chloride gradient. (d) IV relations of currents measured from the AAVp5-cftr infected cells before (open circles) and after stimulation (filled circles). Rectification of current was consistent with the Cl − concentration gradient. (e) Comparison of average conductance measured from cells infected with AAV-cftr, AAVp5-lacZ and increasing doses of AAVp5-cftr. Numbers in parentheses indicate

Discussion
The goal of this study was to develop a new generation of AAV/cftr vectors that could efficiently express CFTR protein in target cells. AAV-based vectors have been demonstrated to be efficient in transferring the CFTR gene into airway epithelial cells in vivo. However, the levels of CFTR expression from the AAV vector were suboptimal, since an efficient promoter could not be incorpor-
Figure 6 Vector packaging assays. AAV-cftr, AAVcmv-cftr, AAVsv-cftr and AAVp5-cftr were packaged into virions under identical conditions. Packaged vector DNA was extracted and analyzed with a Southern blot using a P 32 -labeled probe against cftr. DNA from each vector was indicated at the bottom of each lane. Lane CF is denatured linear cftr cDNA as a positive control and size marker. Lane N is cftr cDNA packaged without AAV ITR as a negative control. The intensities of the bands indicate packaging efficiency of the vectors. AV-cftr is packaged at the optimal level. AAVp5-cftr is packaged more efficiently than AAVsv-cftr. The packaging level of AAVcmv-cftr is minimal.
ated into the vector due to the packaging size restraint. Previous attempts to incorporate additional promoters, include the P5 promoter, into AAV vector have resulted in AAV vectors that were poorly packaged. 29 This is mainly because (1) the vector contained non-essential sequences that occupied some of the precious packaging capacity; (2) the minimal P5 sequence was not identified; and (3) the minimal non-translated sequence required for CFTR expression was not determined. In this study, we have overcome these limitations and developed a strategy to package cftr cDNA with short efficient promoters. Functional analyses demonstrated that CFTR was efficiently expressed from the new AAV vectors containing short promoters but not from the vector in which the CFTR gene was driven by only the ITR sequence of AAV. Using a packaging assay we showed that the new AAV vectors were packaged efficiently into virions and the lack of CFTR expression from the AAV-cftr vector is due to insufficient transcription from the ITR, but not due to vector packaging. In contrast, CFTR carried by an AAV vector that contains P5 or TK promoter was packaged efficiently and expressed at high levels in transduced cells.
We used functional assays to demonstrate the efficient CFTR expression from the new AAV vectors. SPQ assay was specific and sensitive. However, we did not use this assay for the comparison of the levels of CFTR expression to prevent introducing bias into the results. This is because the procedures involve visual selection of positive cells from non-transduced cells and it is difficult to determine the threshold for excluding cells that express CFTR at low levels. Instead, we used whole-cell patch clamp analyses to measure the total Cl − conductance of CFTR channels in randomly selected cells. The levels of the conductance are directly related to the numbers of CFTR molecules in the cell membrane. The number of CFTR molecules can be calculated by dividing the total Cl − conductance with the conductance of a single CF channel. Therefore, patch clamp assays provided us with quantitative measurements of CFTR expression from the AAV vectors. We used HeLa cells for most of the functional assays, because these cells are technically easier for patch clamp measurements and the results are more consistent. Importantly, these cells have been used in previous studies, and their support of CFTR expression is similar to those of airway epithelial cells. Nevertheless, we have also performed patch clamp measurements in JME cells, a ⌬508 homozygote cell line, to demonstrate functional correction of the CFTR defect, and have found no difference in the characteristics of their supporting wild-type CFTR expression. These results further confirmed that ⌬508 phenotype can be corrected by AAVmediated expression of the wild-type CFTR and the mutant protein does not interfere with the functions of the normal CFTR.
Among the three short promoters that we have tested, P5 provide the highest levels of CFTR expression. However, the TK promoter may possess an advantage over P5 promoter, since it lacks any sequences that are homologous to the helper plasmid used in the production of AAV virions. This will reduce the theoretical possibility of generating wild-type virions through homologous recombination. SV40e promoter also lacks the homology to the helper plasmid and is stronger than the TK promoter. However, its utility is limited by the larger size (200) that make it less efficiently packaged into virions with the cftr cDNA, as shown in both CFTR function and packaging assays.
In the titer-expression relation experiment, we showed that CFTR expression at levels similar to normal airway epithelial cells (60 pS/pF) was achieved with MOI of 4. This demonstrated that CFTR is efficiently expressed by the P5 promoter and further supported the notion that higher levels of CFTR expression from AAV vectors may be beneficial since the MOI which can be achieved in vivo is often limited.
As AAV vector has been shown to persistently infect airway epithelial cells in animal models and in human trials, it is our hope that higher levels of CFTR expression from the new vectors will provide better therapeutic efficacy than the current AAV vectors in the studies of CF gene therapy.
Materials and methods
Cells and vectors
HeLa cells were obtained from the American Type Culture Collection (Rockville, MD, USA). The cells were maintained in DMEM media (GIBCO, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (GIBCO).
AAV vectors containing the CFTR minigene were constructed by first inserting the down-sized CFTR cDNA into pPTK65TK which contains the HSVtk gene promoter followed by a truncated tk gene polyadenylation (poly-
Figure 7 Whole cell patch clamp recording from a JME cell (⌬F508/⌬F508) infected with AAV P5CFTR or mock-infected cell (no virus). Forskolin (Fsk, 10 m) stimulated Cl current in infected cell (top trace) but had no effect in uninfected cell (bottom trace). Recordings were done with a 19:150 mm C1 gradient from pipette to bath as a driving force and was clamped to zero mV. The traces are typical of three recordings in cells transduced with AAVp5-cftr and four recordings in uninfected cells. Current voltage relations were recorded during breaks in current trace. (a) The C1 current (120 pA) was stimulated by forskolin (10 m), and can be blocked by the Cl channel blocker diphenylcarboxylate (+DPC, 2 mm). Wash-out of DPC (−) recovered current parially. Uninfected control cells showed no forskolin-activated currents (bottom trace). (b) Reording from 16HBE14o− airway cells. These cells express normal CFTR and have characteristics of airway surface epithelial cells. Stimulation with forskolin (10 m) activated Cl currents (130 pA) comparable to those in transduced JME cells. (c) Current step protocols show time-independent currents (typical for CFTR) after stimulation with forskolin in AAVp5-cftr infected cells, but not in control cells. (d) Current voltage relations showed typical Goldman rectification after forskolinstimulation (filled circles). Chloride conductance values at zero mV were 0.22 nS (control, open circles), and 2.02 nS (forskolin, filled circles).
A) signal of 65 bp in size. The transcriptional cassette containing the CFTR gene was then inserted into an AAV vector, pAV53 (to be published). This vector contains the two ITRs sequences of AAV. These sequences and part of the linker sequences were 302 bp in total length. The P5 promoter is 150 bp in length containing AAV sequence from 146 to 296 bp.
The short forms of promoter and poly-A sequences were isolated with PCR amplification. The 3′-end of each promoter sequence is the +1 location (RNA capping site). The length of each promoter indicates the 5Ј-end location of the promoter fragment. The TK1 promoter contains the −110 to +1 of HSVtk promoter sequences; TK 2 contains the same region but with a 10 bp deletion from −65X to −75. The TK65/poly-A was isolated from the poly-A sequence of the tk gene. It contains 3 bp upstream and 56 bp downstream of the conserved AATAAA sequence.
Transducing AAV virions were prepared using the method we have published previously. 31 A helper plasmid, p72TPrc that contains the rep-cap genes of AAV cloned in a small plasmid was used for all experiments that involved AAV production. AAV vector containing CFTR gene were mixed with the helper DNA at a vector to helper ratio of 1 to 15 and transfected into HeLa cells with Lipofectamine procedure (GIBCO) according to the manufacturer's protocol.
Reduction in the size of CFTR cDNA The cDNA coding for the CFTR is over 7.2 kb. It has been reduced to 4.7 kb by removing most of the untranslated regions. Since the coding sequence of the cDNA (from start codon to stop codon) was 4443 bp, 1 we further reduced the size of cftr cDNA from 4.7 kb to 4467 bp. This was done by creating a novel SpeI cleavage site 20 bp upstream of the Kozak sequence and a XhoI site immediately downstream of the stop codon (CFTR4.5). These truncations were made by PCR amplification with primers containing the synthetic cloning sites. The CFTR4.5 DNA fragment was further cloned into pTK1 or pP5TK which contained the minimal HSVtk or AAV P5 promoter and a TK poly-A. The TKcftr or P5cftr transcription cassette was then inserted into an AAV vector, pAV53 (unpublished) with XbaI and XhoI sites. The vector structures and cloning procedures are shown in Figure 7 . The resulting vector, AAVtk-cftr or AAVp5-cftr, contains only the ITRs from AAV and the shortened CFTR cDNA within the minimal TK or P5 transcription cassettes.
AAV vector production and cell transduction Recombinant AAV virions were produced with a transfection protocol similar to that described previously. 38, 39 Briefly, AAVtk.cftr or AAVp5-cftr vector was co-transfected with a helper plasmid, p72 TPrC 38 at a helper/vector ratio of 19:1. A total of 10 g of DNA was transfected into HeLa cells in each 100-mm dish (Falcon). DNA transfections were performed with the Lipofectamine procedure (GIBCO) according to the manufacturer's protocol. Cells were lysed by freezing and thawing three times, followed by a 30-s sonication using an ultrasonicator at 30% of output (Sonifier 450, Branson, Danbury, CT, USA). Cell lysates were then centrifuged in an Eppendorf (Brinkmann Instruments, Westbury, NY, USA) microfuge for 5 min at 12 000 r.p.m. to remove cell debris. Infectious vector titers were estimated by comparing DNA content with an AAVcmvLacZ virus using dot blot. The infectious titer of the standard AAVcmvLacZ virus had been determined by counting the lacZ-positive cells after infection. For gene transfer assays, cells were infected at MOI of 5-10. The characteristics of the AAV-mediated CFTR expression were analyzed with single-channel patch clamp, under cell attached or detached conditions as described in detail previously. 40 Briefly, cells were placed in an open, constantly perfused and heated chamber (37°C) on the stage of an inverted microscope. Solutions were designed to measure chloride currents only. In the cell-attached mode bath and pipette were filled with a solution containing: 145 mm N-methyl-d-glutamime chloride (NMDGCl), 1.7 mm CaCl 2 , 1 mm MgCl, 10 mm Hepes, 10 mm glucose and pH = 7. 
Vector packaging assay
The packaging efficiencies of the AAV vectors were compared with Southern blot analysis. AAV virions containing different AAV/cftr vectors were prepared under identical conditions and 10 l of each viral suspension was used to infect cells in 60-mm plate. The adenovirus in the vector preparation was heat-inactivated at 50°C for 15 min. Infected HeLa cells were incubated for 6 h to allow uncoating of the virions. Single-strand vector DNAs were extracted using a modified Hirt's extraction as described previously. 41 Vector DNA was analyzed on a Southern blot using a DNA probe corresponding to the CFTR coding sequence. The probe was labeled with 32 P using a Rediprime system according to the manufacturer's protocol (Amersham, Arlington Heights, IL, USA). Conditions for hybridization were 65°C, 5X SSC, 1X Denhardt's solution, and 10 g/ml sheared herring sperm DNA. Hybond membrane with the transferred vector DNA was hybridized with the probe for 15 h and washed twice at 55°C in 2 × SSC, 0.2% SDS for 30 min and then twice in 0.2 × SSC, 0.2% SDS for 30 min.
